BRCA1 and ovarian serous carcinoma: BRCA1/2 mutations regained clinical attention, as patients with high-grade serous ovarian carcinomas with pathogenic BRCA1/2 mutations displayed improved overall and recurrence-free survival if treated with platinum-based therapy in combination with PARP inhibitors such as olaparib (Hennessy et al. 2010; Mafficini et al. 2016; Moschetta et al. 2016; Muggia 2009; Oza et al. 2015; Kwon et al. 2010; Muggia et al. 2011).